Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) is projected to release its earnings data before the market opens on Monday, March 17th. Analysts expect Abeona Therapeutics to post earnings of ($0.35) per share and revenue of $0.10 million for the quarter.
Abeona Therapeutics Price Performance
Abeona Therapeutics stock opened at $5.29 on Friday. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $8.87. The stock has a market capitalization of $229.96 million, a P/E ratio of -1.97 and a beta of 1.79. The firm’s 50-day moving average is $5.51 and its two-hundred day moving average is $5.84. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Oppenheimer assumed coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Wednesday, February 19th. Finally, StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 22nd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.50.
About Abeona Therapeutics
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Featured Stories
- Five stocks we like better than Abeona Therapeutics
- What is diluted earnings per share (Diluted EPS)?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are Dividend Challengers?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Do S&P 500 Stocks Tell Investors About the Market?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
